Adaptimmune Announces Initiation of Myxoid/Round Cell Liposarcoma Study

PHILADELPHIA and OXFORD, United Kingdom, Dec. 05, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that it has initiated a study of its NY-ESO SPEAR(TM) T-cells in myxoid/round cell liposarcoma (MRCLS). Patient...

London, 05/12/2016 (informazione.it - comunicati stampa - salute e benessere)